
1. j trop med hyg. 2020 may;102(5):1056-1063. doi: 10.4269/ajtmh.19-0954.

artemether-lumefantrine efficacy treatment uncomplicated plasmodium
falciparum malaria choco, colombia 8 years first-line treatment.

olivera mj(1), guerra ap(1), cortes lj(1), horth rz(2), padilla j(3), novoa j(4),
ade mp(5), ljolje d(6), lucchi nw(6), marquiño w(4), renteria m(7), yurgaky w(8),
macedo de oliveira a(6).

author information: 
(1)grupo de parasitología, instituto nacional de salud, bogota, colombia.
(2)epidemic intelligence service, center surveillance, epidemiology, and
laboratory services, centers disease control prevention, atlanta,
georgia.
(3)ministerio de salud protección social, bogota, colombia.
(4)pan-american health organization, bogota, colombia.
(5)department communicable diseases environmental determinants health, 
pan-american health organization, washington, district columbia.
(6)malaria branch, division parasitic diseases malaria, center global 
health, centers disease control prevention, atlanta, georgia.
(7)laboratorio departamental de salud pública de choco, quibdo, colombia.
(8)hospital ismael roldan valencia ese, quibdo, colombia.

artemether-lumefantrine (al) first-line treatment uncomplicated
plasmodium falciparum infection colombia. assess al efficacy for
uncomplicated falciparum malaria quibdo, choco, colombia, conducted a
28-day therapeutic efficacy study (tes) following guidelines. july
2018 february 2019, febrile patients aged 5-65 years microscopy-confirmed
p. falciparum mono-infection asexual parasite density 250-100,000
parasites/µl enrolled treated supervised 3-day course al. 
primary endpoint adequate clinical parasitological response (acpr) day
28. attempted use polymerase chain reaction (pcr) genotyping to
differentiate reinfection recrudescence, conducted genetic testing for
antimalarial resistance-associated genes. eighty-eight patients consented and
were enrolled; four lost follow-up missed treatment doses. therefore, 
84 (95.5%) participants reached valid endpoint: treatment failure acpr. no
patient remained microscopy positive malaria day 3, evidence delayed
parasite clearance artemisinin resistance. one patient recurrent
infection (12 parasites/µl) day 28. uncorrected acpr rate 98.8% (83/84)
(95% ci: 93.5-100%). recurrent infection sample amplify during
molecular testing, giving pcr-corrected acpr 100% (83/83) (95% ci:
95.7-100%). p. falciparum kelch 13 polymorphisms associated artemisinin
resistance identified. results support high al efficacy falciparum
malaria choco. time required conduct tess low-endemic
settings, important consider complementary alternatives monitor
antimalarial efficacy resistance.

doi: 10.4269/ajtmh.19-0954 
pmcid: pmc7204575 [available 2021-05-01]
pmid: 32100686  [indexed medline]

